NewslettersMay 02, 2025
Porton Newsletter - April 2025 Recap
Technical Enabling Services & Solutions Company Events Marketing Activities
News Apr 16, 2025
Porton Advanced's End-to-End CDMO Solutions Accelerates IND Approval of Tasly's Innovative Dual-Targeting CAR-T Therapy
April 12, 2025 - Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD’s Innovative Dual-Targeting CAR-T Therapy, "P134 Cell Injection," which has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) (Approval No.: 2025LP01030). This breakthrough CAR-T therapy is indicated for recurrent glioblastoma (GBM).
NewslettersApr 11, 2025
Porton Newsletter - March 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities
NewslettersApr 11, 2025
Porton Newsletter - Q1 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities
News Mar 21, 2025
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News Mar 19, 2025
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
News Mar 07, 2025
Porton Wins Outsourced Pharma 2025 CDMO Leadership Award
In March 2025, Porton Pharma Solutions Ltd. was honored with the "Global Small Molecule API Award" at the 14th Outsourced Pharma CDMO Leadership Awards, recognizing its exceptional end-to-end services across the global small molecule drug lifecycle. This award reaffirms Porton's outstanding performance in the CDMO sector for pharmaceutical R&D and manufacturing worldwide.
News Mar 07, 2025
DCAT Week 2025 — The Premier Event Connecting Biotech and Pharmaceutical Industries
DCAT Week is the premier annual event for the biotechnology and pharmaceutical manufacturing value chain. With senior decision-makers in attendance, it provides a unique platform for healthcare companies of all sizes to conduct high-level business meetings and foster strategic partnerships.
NewslettersMar 06, 2025
Porton Newsletter - Jan. to Feb. 2025 Recap
Technical Enabling Technical Solutions for PROTAC Drugs Successful GMP Drug Product Delivery by Porton Biologics and Conjugates Platform
